Funding is in the form of one SBIR Phase 1 award titled ‘effects of P-188 on respiratory function and diaphragm degeneration in the mdx mouse’ and STTR phase 1 award titled ‘Poloxamer 188 mechanism of action in ischemic heart failure.’
Phrixus Pharma CEO and president Thomas Collet said this funding constitutes validation for the potential utility of Carmeseal not just in cardiomyopathy but also in respiratory disease in patients with DMD, for whom it is the leading killer.
Carmeseal known as poloxamer 188 (P-188), acts as a molecular bandaid which increases the blood pumping capacity of the damaged hearts.
Carmeseal is infused into the bloodstream which prevents the pathological leak of calcium into the heart cells, which could cause calcium overload and keep the heart from delivering sufficient oxygenation to the vital organs.